Paratek Pharmaceuticals
Boston, MA, United StatesIndustry
Paratek Pharmaceuticals develops antibiotics including for biothreat pathogens. CBRNE-relevant work is a minor part of its offering according to its website. It is headquartered in Boston, MA, United States.
What it does
Threats covered
Categories
Profile
Paratek Pharmaceuticals is a Boston-area pharmaceutical company that Gurnet Point Capital and Novo Holdings acquired on 21 September 2023 for about 462 million dollars, after which it became a wholly owned subsidiary and was delisted. Its antibiotic NUZYRA (omadacycline), available as an oral and intravenous medicine, is supported by a BARDA Project BioShield contract for development and US manufacturing for the treatment and post-exposure prophylaxis of pulmonary anthrax.
More profile
The contract was first awarded in 2019 and is valued at up to 304 million dollars, including procurement of up to 10,000 treatment courses. A 2024 notice records that Paratek completed onshoring of NUZYRA manufacture under the contract.
NUZYRA is also sold commercially for bacterial infections. The founding year was not read.
Ownership
Private; acquired on 21 September 2023 by Gurnet Point Capital and Novo Holdings for about 462 million dollars and delisted
Parent: Gurnet Point Capital and Novo Holdings (checked)
Sources (5)
- https://www.sec.gov/Archives/edgar/data/1178711/000119312523239185/d524523d8k.htm
- https://www.globenewswire.com/news-release/2023/09/21/2747312/33636/en/gurnet-point-capital-and-novo-holdings-a-s-complete-acquisition-of-paratek-pharmaceuticals-inc.html
- https://www.globenewswire.com/news-release/2023/07/10/2701714/33636/en/Paratek-Pharmaceuticals-Announces-Modification-of-BARDA-Contract-to-Advance-the-Development-of-NUZYRA-omadacycline-for-Post-Exposure-Prophylaxis-PEP-and-Treatment-of-Pulmonary-Anth.html
- https://medicalcountermeasures.gov/newsroom/2024/paratek
- https://www.sec.gov/Archives/edgar/data/1178711/000156459019046331/prtk-ex991_183.htm
Not verified or not found
- Founding year: not read.
- Headquarters city: the sheet states Boston; the corporate address was not read in these sources.
- Status of the BARDA procurement since 2024: not read.
Questions
What does Paratek Pharmaceuticals do?
Paratek Pharmaceuticals develops antibiotics including for biothreat pathogens. CBRNE-relevant work is a minor part of its offering according to its website.
Where is Paratek Pharmaceuticals based?
HQ (as found): Boston, MA. HQ country: US.
Who owns Paratek Pharmaceuticals?
Private; acquired on 21 September 2023 by Gurnet Point Capital and Novo Holdings for about 462 million dollars and delisted. Parent: Gurnet Point Capital and Novo Holdings (checked)
Profiles are compiled from public sources and sampled-checked, not fully audited. Last verified 17 October 2026. Report a correction